Vidutolimod
Metastatic Prostate Adenocarcinoma
Emory Universitynucleic_acidPhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 30/ 100
- Competitive Position
- 81/ 100
Competitive context
15 Active assets in the Metastatic Prostate Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VIPIVOTIDE TETRAXETAN Mayo Clinic | Phase 3 | BB |
Niraparib Mayo Clinic | Phase 2 | B |
Lipitor Tampere University Hospital | Phase 3 | B |
Talzenna Prostate Cancer Clinical Trials Consortium | Phase 2 | B |
Rucaparib Alliance for Clinical Trials in Oncology | Phase 3 | B |
View all 22 →
Same molecule, other indications
Vidutolimod is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →